- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02489747
Effects of Wheat Bran Extract on Cognitive and Memory Function
Efficacy and Safety of Wheat Bran Extract on Improvement of Cognitive and Memory Function
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Based on reports about the neuroprotective effects of water extract from wheat Triticum aestivum L. or its bran, the investigators hypothesize that extract of wheat bran (WBE) is beneficial to elderly people with age-associated cognitive impairment. The investigators investigated the efficacy and safety of WBE on improvement of cognitive function through measuring the neuropsychometric assessments in adult with subjective cognitive impairment by a randomized clinical trial.
Seventy participants aged from 50 to 80 years old with subjective cognitive impairment were randomly assigned to receive either WBE (3,000 mg/day) in this 12-week, double-blind placebo-controlled and parallel trial. Neuropsychological assessments including Computerized Neurocognitive function test (CNT), Working Memory Test (WMT), Korean Mini-Mental State Examination (K-MMSE), Brief Cognitive Rating Scale (BCRS), Prospective and Retrospective Memory Questionnaire (PRMQ), Perceived Stress Scale (PSS), 36-Item of Short-Form Health Survey (SF-36) and blood Brain-derived neurotrophic factor (BDNF) were used to assess the cognitive function before and after the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subjects with subjective cognitive impairment
- able to give informed consent
Exclusion Criteria:
- history of underlying neurodegenerative disease
- allergic or hypersensitive to any of the ingredients in the test products
- history of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
- history of alcohol or substance abuse
- participation in any other clinical trials within past 2 months
- laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
placebo
|
Placebo
|
Experimental: WBE group
wheat bran extract
|
wheat bran extract (3 g/day)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cognitive function as assessed by the visual learning test score of CNT (computerized neurocognitive test)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Visual subset of WMT (working memory test)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Cognitive function as assessed by the CNT (Computerized Neurocognitive Test) score
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Cognitive function as assessed by the Verbal subtest of WMT (Working Memory Test)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Cognitive function as assessed by the BCRS (Brief Cognitive Rating Sclae)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Memory function as assessed by the PRMQ (Prospective and Retrospective Memory Questionnaire)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Stress level evaluation as assessed by the Perceived stress scale (PSS)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Quality of life as assessed by the 36-item short-form healthy survey (SF-36) score
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Cognitive function as assessed by the Brain-Derived Neurotrophic Factor (BDNF)
Time Frame: baseline and 12 weeks
|
baseline and 12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CTCF2_2013_WBE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Function 1, Social
-
Pontificia Universidad Catolica de ValparaisoCompletedCognitive Function 1, SocialChile
-
Massachusetts General HospitalCompleted
-
University of Illinois at Urbana-ChampaignUniversity of Illinois at Chicago; National Institute on Aging (NIA)Recruiting
-
Huie-Ling ChiuCompletedCognitive Function 1, SocialTaiwan
-
Federal University of São PauloUniversity of Sao PauloCompletedCognitive Function 1, Social
-
Philips Electronics Nederland B.V. acting through...Qserve; Dent Neurologic InstituteCompleted
-
University of BarcelonaUniversity of Pittsburgh; Germans Trias i Pujol Hospital; Ministerio de Economía... and other collaboratorsCompletedAging | Cognitive Function 1, SocialSpain
-
University of PittsburghNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedHealthy | Cognitive Function 1, SocialUnited States
-
Psychiatric University Hospital, ZurichUniversity of BaselCompletedEmotions | Mood | Cognitive Function 1, Social | EmpathySwitzerland
-
St. Mary's University, TwickenhamRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States